Health

Results: 589-600 of 8097

Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million

Abbelight Announces Successful Series B Investment led by AVANT BIO to Accelerate Imaging Innovation and Scale Adoption Across a Broader Customer Base

PR Newswire associated0

Cumulus Neuroscience Appoints Ricardo Sáinz Fuertes, MD as New Board Chair

Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC

PR Newswire associated0

Sky Labs Secures CE-MDR for 'CART PLATFORM,' Accelerating Its Global Market Entry

Arne Boye Nielsen

Natus Sensory Appoints Arne Boye Nielsen to Board of Directors

4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US).

4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics

Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference

Dr. Anand Tharmaratnam, Novotech CEO and Chairman

Novotech Appoints Anand Tharmaratnam as New CEO

PR Newswire associated0

LabConnect Establishes New Global Headquarters in Raleigh-Durham Area

Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data